| Medical and Health Sciences | Lifetime | 301 | US 166 | 99.99 |
| Ophthalmology | Lifetime | 5 | US 3 | 99.97 |
| Radiology, Nuclear Medicine and Imaging | Lifetime | 187 | US 111 | 99.53 |
| Oncology | Lifetime | 255 | US 146 | 99.59 |
| Surgery | Lifetime | 819 | US 441 | 99.22 |
| Pulmonary and Respiratory Medicine | Lifetime | 794 | US 410 | 98.78 |
| Clinical Neurology | Lifetime | 462 | US 208 | 98.03 |
| Genetics | Lifetime | 870 | US 449 | 97.86 |
| Dermatology | Lifetime | 405 | US 160 | 97.10 |
| Medical Genetics | Lifetime | 508 | US 252 | 95.15 |
| Pathology and Forensic Medicine | Lifetime | 953 | US 429 | 95.13 |
| Ophthalmology | 2021-2025 | 16 | US 8 | 99.50 |
| Oncology | 2021-2025 | 514 | US 227 | 93.04 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 924 | US 340 | 87.27 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 808 | US 276 | 80.61 |
| Clinical Neurology | 2021-2025 | 598 | US 229 | 72.21 |
| Dermatology | 2021-2025 | 377 | US 131 | 55.48 |
| Cell Biology | 2021-2025 | 308 | US 121 | 49.09 |
| Ocular Oncology and Treatments | Lifetime | 1 | US 1 | 99.90 |
| Nonmelanoma Skin Cancer Studies | Lifetime | 3 | US 1 | 99.87 |
| Ocular Disorders and Treatments | Lifetime | 1 | US 1 | 99.85 |
| Ocular Infections and Treatments | Lifetime | 3 | US 3 | 99.87 |
| Retinal Development and Disorders | Lifetime | 7 | US 6 | 99.82 |
| Retinal and Macular Surgery | Lifetime | 3 | US 3 | 99.86 |
| Cancer and Skin Lesions | Lifetime | 9 | US 7 | 99.74 |
| Corneal Surgery and Treatments | Lifetime | 7 | US 4 | 99.79 |
| Glaucoma and retinal disorders | Lifetime | 17 | US 11 | 99.86 |
| Head and Neck Surgical Oncology | Lifetime | 11 | US 11 | 99.85 |
| Brain Metastases and Treatment | Lifetime | 14 | US 11 | 99.81 |
| Cutaneous Melanoma Detection and Management | Lifetime | 13 | US 5 | 99.83 |
| Ear and Head Tumors | Lifetime | 14 | US 10 | 99.68 |
| Retinal Diseases and Treatments | Lifetime | 41 | US 28 | 99.73 |
| Ocular Diseases and Behçet’s Syndrome | Lifetime | 26 | US 16 | 99.64 |
| Glioma Diagnosis and Treatment | Lifetime | 117 | US 74 | 99.54 |
| Vascular Tumors and Angiosarcomas | Lifetime | 24 | US 13 | 99.56 |
| CNS Lymphoma Diagnosis and Treatment | Lifetime | 30 | US 15 | 99.51 |
| Vascular Malformations and Hemangiomas | Lifetime | 36 | US 23 | 98.80 |
| Retinal and Optic Conditions | Lifetime | 79 | US 41 | 99.38 |
| melanin and skin pigmentation | Lifetime | 65 | US 29 | 98.90 |
| Genetic and rare skin diseases. | Lifetime | 29 | US 17 | 98.92 |
| Histiocytic Disorders and Treatments | Lifetime | 34 | US 20 | 98.86 |
| Soft tissue tumor case studies | Lifetime | 73 | US 44 | 98.88 |
| Tuberous Sclerosis Complex Research | Lifetime | 36 | US 26 | 97.79 |
| Nasolacrimal Duct Obstruction Treatments | Lifetime | 17 | US 6 | 97.87 |
| Optical Coherence Tomography Applications | Lifetime | 147 | US 68 | 98.13 |
| Cancer-related Molecular Pathways | Lifetime | 516 | US 294 | 98.21 |
| Salivary Gland Tumors Diagnosis and Treatment | Lifetime | 303 | US 151 | 98.01 |
| Drug-Induced Ocular Toxicity | Lifetime | 30 | US 16 | 96.91 |
| Neurofibromatosis and Schwannoma Cases | Lifetime | 244 | US 137 | 97.32 |
| Facial Trauma and Fracture Management | Lifetime | 266 | US 105 | 96.45 |
| Bone Tumor Diagnosis and Treatments | Lifetime | 593 | US 285 | 96.35 |
| Meningioma and schwannoma management | Lifetime | 745 | US 355 | 96.52 |
| Vascular Malformations Diagnosis and Treatment | Lifetime | 571 | US 285 | 96.40 |
| Teratomas and Epidermoid Cysts | Lifetime | 123 | US 79 | 94.48 |
| Hedgehog Signaling Pathway Studies | Lifetime | 549 | US 259 | 93.46 |
| Polyomavirus and related diseases | Lifetime | 876 | US 414 | 94.06 |
| Tumors and Oncological Cases | Lifetime | 815 | US 411 | 93.24 |
| Melanoma and MAPK Pathways | Lifetime | 924 | US 449 | 91.83 |
| IgG4-Related and Inflammatory Diseases | Lifetime | 404 | US 94 | 89.46 |
| Soft tissue tumors and treatment | Lifetime | 265 | US 122 | 86.02 |
| Infectious Disease Case Reports and Treatments | Lifetime | 520 | US 255 | 73.22 |
| Ocular Oncology and Treatments | 2021-2025 | 3 | US 3 | 99.15 |
| Brain Metastases and Treatment | 2021-2025 | 53 | US 29 | 97.76 |
| Cutaneous Melanoma Detection and Management | 2021-2025 | 52 | US 8 | 98.10 |
| Ear and Head Tumors | 2021-2025 | 69 | US 25 | 93.10 |
| Nonmelanoma Skin Cancer Studies | 2021-2025 | 118 | US 26 | 94.07 |
| Vascular Tumors and Angiosarcomas | 2021-2025 | 53 | US 19 | 93.79 |
| Glaucoma and retinal disorders | 2021-2025 | 487 | US 128 | 94.79 |
| CNS Lymphoma Diagnosis and Treatment | 2021-2025 | 172 | US 76 | 90.05 |
| Retinal Development and Disorders | 2021-2025 | 632 | US 230 | 84.15 |
| Cancer-related Molecular Pathways | 2021-2025 | 611 | US 204 | 77.84 |
| Retinal and Macular Surgery | 2021-2025 | 472 | US 105 | 80.21 |
| Ocular Infections and Treatments | 2021-2025 | 415 | US 102 | 75.64 |
| Cancer and Skin Lesions | 2021-2025 | 607 | US 186 | 71.57 |
| Histiocytic Disorders and Treatments | 2021-2025 | 416 | US 161 | 55.65 |
| Nasolacrimal Duct Obstruction Treatments | 2021-2025 | 293 | US 34 | 26.08 |
